(Q34492381)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26337614%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

title

Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26337614%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26337614%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Ji-chun Zhang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26337614%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Wei Yao

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26337614%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Chao Dong

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26337614%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Chun Yang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26337614%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Qian Ren

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26337614%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Min Ma

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26337614%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Mei Han

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26337614%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

publication date

4 September 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26337614%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26337614%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

232

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26337614%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26337614%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

4325-4335

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26337614%20AND%20SRC:MED&resulttype=core&format=json

Ketamine for depression: where do we go from here?

23 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Antidepressant effects of ketamine in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Neurotrophins and psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Synaptic dysfunction in depression: potential therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

A neurotrophic model for stress-related mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

The role of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in depression: central mediators of pathophysiology and antidepressant activity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

A standardized protocol for repeated social defeat stress in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Emerging role of glutamate in the pathophysiology of major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

The role of glutamate on the action of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

The R-Stereoisomer of Ketamine as an Alternative for Ketamine for Treatment-resistant Major Depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Inflammatory biomarkers as differential predictors of antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Increased levels of glutamate in brains from patients with mood disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

The serotonin-BDNF duo: developmental implications for the vulnerability to psychopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

BDNF release is required for the behavioral actions of ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Antidepressant Effects of Ketamine on Depression-like Behavior in Juvenile Mice after Neonatal Dexamethasone Exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Effects of Brilliant Blue G on Serum Tumor Necrosis Factor-α Levels and Depression-like Behavior in Mice after Lipopolysaccharide Administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

The mesolimbic dopamine reward circuit in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Neurobiology of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Glutamate Signaling in Synaptogenesis and NMDA Receptors as Potential Therapeutic Targets for Psychiatric Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Effects of TrkB agonist 7,8-dihydroxyflavone on sensory gating deficits in mice after administration of methamphetamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

7,8-Dihydroxyflavone, a TrkB agonist, attenuates behavioral abnormalities and neurotoxicity in mice after administration of methamphetamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Chronopharmacological studies of ketamine in normal and NMDA epsilon1 receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Alterations in brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in the brain regions of a learned helplessness rat model and the antidepressant effects of a TrkB agonist and antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Glutamate-based antidepressants: 20 years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Roles of glutamate signaling in preclinical and/or mechanistic models of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Rapid antidepressant effects and abuse liability of ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Regional differences in brain-derived neurotrophic factor levels and dendritic spine density confer resilience to inescapable stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Effects of amycenone on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Glutamatergic modulators: the future of treating mood disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Effects of chronic social defeat stress on behavior and choline acetyltransferase, 78-kDa glucose-regulated protein, and CCAAT/enhancer-binding protein (C/EBP) homologous protein in adult mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-015-4062-3

Critical role of brain-derived neurotrophic factor in mood disorders

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26337614

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26337614